Podcasts about Novo Nordisk

It's In the News.. a look at the top headlines and stories in the diabetes community. This week's top stories: kids' A1C and tech access correlation, first generic GLP-1 for weight loss approved, Metformin cuts long covid risk, Tandem Diabetes & Eversense updates, and more! Find out more about Moms' Night Out  Please visit our Sponsors & Partners - they help make the show possible! Learn more about Gvoke Glucagon Gvoke HypoPen® (glucagon injection): Glucagon Injection For Very Low Blood Sugar (gvokeglucagon.com) Omnipod - Simplify Life Learn about Dexcom   Check out VIVI Cap to protect your insulin from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Twitter Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com  Reach out with questions or comments: info@diabetes-connections.com Episode transcription with links:   Hello and welcome to Diabetes Connections In the News! I'm Stacey Simms and every other Friday I bring you a short episode with the top diabetes stories and headlines happening now. XX Accessibility to modern diabetes technology directly correlates with A1c among children with type 1 diabetes globally. Big, cross-sectional study, conducted in 81 pediatric diabetes centers in 56 countries, found that a greater extent of reimbursement for continuous glucose monitoring (CGM), insulin pumps, glucose meters, and insulin was associated with lower A1c levels. Partha S. Kar, MD, Type 1 Diabetes & Technology lead of the National Health Service England, told Medscape Medical News, “As is now being shown in countries such as UK with widespread uptake of technology, there is now population-wide shift in A1c not seen before.”   He added, “If policymakers are serious about bringing A1c at a population level to sub-7.5% - 8% levels, then without technology it would be incredibly difficult to achieve, in my experience and opinion. Leaving the median A1c of a population at above 7.5%-8% goes with complications so that's a decision regarding investment many will have to make in the near future.”   In an accompanying editorial, Elizabeth R. Seaquist, MD, professor of diabetes, endocrinology, and metabolism and co-director of the Institute for Diabetes, Obesity, and Metabolism at the University of Minnesota, Minneapolis, called it “striking” that access to technology in and of itself was associated with improved glycemic control, given that multidisciplinary team care is also needed to provide education and behavioral or psychological support.     https://www.medscape.com/viewarticle/diabetes-tech-access-linked-a1c-kids-t1d-globally-2025a1000nn6 XX A man with type 1 in Illinois has received the first FDA-approved islet-cell replacement treatment, Lantidra, and  he is now producing his own insulin. The treatment works by restoring the body's beta cells, potentially eliminating the need for insulin injections.   The FDA approved Lantidra (donislecel) in 2023. Lantidra uses donor cells and requires lifelong immunosuppressive drugs.     Lantidra is only available at University of Illinois Chicago Health. Other universities, such as the University of Pennsylvania, continue to do islet cell transplants as part of clinical trials. Early data has shown that a majority of participants in the Lantidra clinical study were able to achieve some level of insulin independence, but it's unclear whether the benefits of donislecel outweigh the treatment's safety risks. Nearly 87 percent of participants reported infection-related adverse events, and post-operation complications included liver lacerations, bruising of the liver (hepatic hematoma), and anemia. One patient died of multi-organ failure from sepsis, which Lantidra maker CellTrans stated was “probably related” to the use of either immunosuppression or study drugs.   In addition, some industry leaders have raised the question of whether it's ethical to commercialize the use of deceased donor islet cells. https://diatribe.org/diabetes-research/first-fda-approved-islet-cell-transplant-performed?utm_campaign=feed&utm_medium=social&utm_source=later   XX Patients in the U.S. now have access to the first generic GLP-1 treatment approved for weight loss as Teva has launched its copycat of Novo Nordisk's injected Saxenda (liraglutide).   The compound, which is a GLP-1 forerunner of Novo's semaglutide products Ozempic and Wegovy, has been approved by the FDA to treat adults with obesity and those who are overweight and have weight-related medical problems.     Saxenda also is endorsed for pediatric patients ages 12 through 17 who are obese and weigh at least 60 kg (132 pounds). The treatment is for both triggering and maintaining weight loss. Saxenda is not the first GLP-1 drug that is available as a generic. In June of last year, Teva also was the first company to launch a knockoff version of Novo's Victoza, which is the same compound as Saxenda but has been approved only for patients with Type 2 diabetes. Sales of the branded versions of both Victoza and Saxenda have declined significantly in recent years as demand for Novo's semaglutide and Eli Lilly's tirzepatide products have skyrocketed. In addition, marketers of compounded products have been aggressively competing for market share in the GLP-1 space. https://www.fiercepharma.com/pharma/saxenda-knockoff-teva-launches-first-generic-glp-1-obesity   XX Metformin could cut the risk of Long COVID by 64% in overweight or obese adults who started the drug within 90 days of infection. The large observational study, published in Clinical Infectious Diseases, analysed health records of over 624,000 UK adults with COVID-19 between March 2020 and July 2023. Among these, nearly 3,000 patients who began metformin treatment soon after diagnosis were tracked for a year. Compared to non-users, their likelihood of developing Long COVID, defined as persistent symptoms 90 days or more after infection, was dramatically lower. https://www.ndtv.com/health/metformin-cuts-risk-of-long-covid-by-64-why-the-diabetes-pill-is-not-for-everyone-9242332 XX Forty-four percent of people age 15 and older living with diabetes are undiagnosed, so they don't know they have it, according to data analysis published Monday in the journal The Lancet Diabetes & Endocrinology. The study looked at data from 204 countries and territories from 2000 to 2023 in a systematic review of published literature and surveys. “The majority of people with diabetes that we report on in the study have type 2 diabetes,” said Lauryn Stafford , the lead author of the study.   “We found that 56% of people with diabetes are aware that they have the condition,” said Stafford, a researcher for the Institute for Health Metrics and Evaluation. “Globally, there's a lot of variation geographically, and also by age. So, generally, higher-income countries were doing better at diagnosing people than low- and middle-income countries.” People under 35 years were much less likely to be diagnosed if they had diabetes than people in middle age or older. Just “20% of young adults with diabetes were aware of their condition,” Stafford said. https://www.cnn.com/2025/09/08/health/diabetes-undiagnosed-half-of-americans-wellness XX A team of Hong Kong scientists is developing an injectable treatment that could potentially improve blood flow in diabetes patients' feet, in the hopes that it will reduce the need for amputation by rebuilding tissue in the arteries.   They also hope to apply the treatment to peripheral artery disease or PAD, a condition caused by the build-up of fatty deposits in arteries that affect blood circulation in the feet. “Traditional treatments for people suffering from poor blood flow in their legs are stent implantation or bypass surgery, which is invasive,” said Wong, who is also the co-founder of a biotechnology company called NutrigeneAI. He said it was his dream to turn research in the academic field into actual clinical treatments. But he added that the team still needed three to four years for further research on the treatment.   https://www.scmp.com/news/hong-kong/health-environment/article/3324671/hong-kong-scientists-developing-new-blood-flow-treatment-aid-diabetes-patients XX   Tandem Diabetes announces Health Canada authorization for distribution of the Tandem t:slim mobile application for Android and iPhone users. The Tandem t:slim mobile app allows users to deliver a bolus from their compatible smartphone, and to wirelessly upload their pump data to the cloud-based Tandem Source platform.1 The app is expected to be available later this year.   The Tandem t:slim mobile app will be available for compatible smartphones in the Apple App Store and Google Play store later in 2025. Once available, Tandem will email eligible customers with instructions on how to download and use the app.  https://www.businesswire.com/news/home/20250904665715/en/Tandem-tslim-Mobile-App-Now-Authorized-by-Health-Canada-for-iPhone-and-Android-Phones   XX Some changes to how the Eversense CGM will be rolled out.. right now it's being distributed by Ascensia Diabetes Care.  Senseonics will take back commercial control of the year long implantable CGM on January 1 in the US and expanding worldwide throughout 2026. The change was a mutual decision, according to the two companies, which said they have signed a memorandum of understanding before a definitive agreement is hammered out by the end of the year. To get started, Senseonics is also set to acquire members of Ascensia's commercial staff—including its CGM president, Brian Hansen, who is slated to become Senseonics' new chief commercial officer. https://www.fiercebiotech.com/medtech/senseonics-retake-eversense-cgm-commercial-control-ascensia-diabetes-care XX Utrecht-based medical device company ViCentra has closed an $85 million Series D round of funding led by Innovation Industries, along with existing investors Partners in Equity and Invest-NL. The round also drew support from EQT Life Sciences and Health Innovations.   The recent capital injection will be used to expand ViCentra's manufacturing capabilities, support regulatory approvals, and strengthen commercial rollout across Europe.   The funds will also be used to launch the next-generation Kaleido 2 patch pump in Europe and prepare for entry into the U.S. market.   The global insulin delivery market is growing quickly due to the increasing number of diabetes cases and demand for effective and user-friendly solutions. The market for insulin pumps is projected to exceed $14 billion by 2034. Patch pumps are the fastest-growing segment, signalling a trend toward compact and wearable devices. And here's where ViCentra is positioned to meet this need, offering a user-friendly, sleek design-led alternative to traditional systems.   Kaleido: design-led insulin delivery Kaleido is the smallest and lightest insulin patch pump developed as a lifestyle product with a particular focus on usability and personalisation.   Designed to feel more like personal technology than a traditional medical device, Kaleido features premium materials, and users can select their own favourite aluminium shells from a range of ten preset colour options.   It integrates with Diabeloop's hybrid closed-loop algorithms (DBLG1 and DBLG2) and is compatible with Dexcom CGM sensors, positioning it within the next generation of automated insulin delivery systems.   “Kaleido is a true disruptor — small, discreet, featherlight, and beautifully designed. It empowers people with diabetes by offering a more personal and distinctive choice in both function and style. Built with empathy and precision, it honours those who live with diabetes every day. With this funding, we can now meet surging European demand and fast-track our entry into the U.S. market. This is a pivotal moment — for ViCentra, and for the community we serve,” said Tom Arnold, Chief Executive Officer at ViCentra.   Improving the quality of life for diabetic patients ViCentra, led by Tom Arnold, is on a mission to improve the lives of those with diabetes.   The company reported that demand for Kaleido in Germany, France, and the Netherlands has already exceeded initial expectations.   ViCentra will present updates on Kaleido at the 61st Annual Meeting of the European Association for the Study of Diabetes (EASD), taking place September 15–19, 2025, in Vienna.   The company plans to engage with clinicians, investors, and strategic partners to further its role in the evolving diabetes care landscape.   “ViCentra is redefining insulin pump therapy with a platform that truly centres the user experience – combining clinical performance with design simplicity and wearability,” commented Caaj Greebe, Partner at Innovation Industries. “At Innovation Industries, we invest in pioneering companies that blend world-class technology with clear commercial potential. ViCentra exemplifies this by delivering a next-generation system addressing the urgent need for better treatment options in diabetes care. We're proud to lead this investment round and partner with Tom and the team as they deepen and expand their presence in Europe and prepare for U.S. entry.”   https://techfundingnews.com/dutch-vicentra-secures-85m-to-bring-insulin-patch-pump-to-more-markets/ XX Luna Diabetes announces they've raised more than 23-million dollars in early venture capital to help continue clinical trials and build out its capacity. This is the company that wants to offer a night time only, tiny, temporary insulin pump – to supplement insulin pen use. According to the company, more than 80% of the improvements in blood sugar from automated insulin delivery systems occur while the user is sleeping. Luna launched a pivotal trial late last year. https://www.fiercebiotech.com/medtech/nighttime-insulin-patch-pump-maker-luna-diabetes-raises-236m   XX Following 15 days and 150 fingerpricks, they're here. The results of the “9 sensor samba“. And what a set of a results…   Well maybe that's overplaying it a little.   Let's just say that the outcome of this n=1 experiment wasn't quite what I expected. One of the established players came out much worse than expected, while a newcomer did a lot better.   Let's dig in, and take a look at the variation. https://www.diabettech.com/cgm/the-nine-sensor-samba-results-revealed/   XX Hard work and perseverance define ranch life, but one man in eastern Montana takes it to another level. At 90, he's still living independently on the ranch he built from the ground up. Even more remarkable? He's a type 1 diabetic.   Bob Delp still begins each day just like he did decades ago, waking up on his ranch near Richey, Montana.   “I always thought if I could ever get a ranch and run a hundred cows, that's what I wanted to do from the time I was a kid,” said Delp.   He made that dream real, the hard way; after coming home from the army, he taught school, hayed for seven cents a bale and saved every cent he could.     “I worked at it real hard because I always felt like it was going to be part of getting me to that ranch that I always wanted,” said Delp.   He did it all while managing type 1 diabetes, a diagnosis that came with few answers and little hope back in the 1950s.   “The doctors tell me being a type 1 diabetic for 66 years isn't supposed to happen. Back then, it was a real challenge,” added Delp.   Statistically, it's almost unheard of. Fewer than 90 people in the world have lived more than 70 years with type 1 diabetes.     Bob credits his late wife, Donna, for helping him beat the odds.   “She has been key in that I always ate on time.”   They've faced their share of storms, both in health and out on the land. Not long after moving to Richey, a heavy snowstorm nearly tore everything apart just after they'd stepped out for dinner.   “If Donna hadn't said it was time to eat, we wouldn't have made it out of there. I guess that's one time that made me happy to have diabetes. And I think that saved us,” said Delp.     Now, he still checks his blood sugar daily but trusts his hands more than high-tech insulin pumps.   “I'm not satisfied with the sensors they have today. I just don't think they're accurate.”   To many, Bob's survival is extraordinary. To him, it's luck.   “The genes are there already, I can't change that so I guess I would have to say just lots of good luck,” said Delp.     And through it all, optimism has been his compass.   “You might fumble the ball, but if you're determined to be a winner, you'll recover that fumble someday,” said Delp.   He still welds nearly every day. Not because he has to, but because it keeps him going.   “As long as I keep doing something like this, I will not be in the nursing home,” said Delp.   https://www.kfyrtv.com/2025/08/09/against-all-odds-montana-man-thrives-with-type-1-diabetes-90/ XX Today, Dexcom is building on this belief and breaking new ground with the launch of its first open call across the U.S. and Canada in search of the next diabetes advocates—giving people with all types of diabetes a once-in-a-lifetime opportunity to raise awareness and share their voice on a global scale in the company's World Diabetes Day campaign (Nov. 14) and beyond.  Who is eligible?: Anyone age 2+ living with all types of diabetes or prediabetes can be nominated by themselves or by someone who knows them. Selected candidates will embody strength, advocacy and pride in living with diabetes or prediabetes. Where and how can I nominate myself or someone I know?: Visit Dexcom.com/WorldDiabetesDay When is the deadline to submit a nomination?: Nominations are open from September 10 through September 19 at 12pm PT. What will the selected candidates experience?:   An invite to participate in a World Diabetes Day photoshoot in Los Angeles to have their unique story featured in Dexcom's World Diabetes Day campaign The ongoing opportunity to attend events, connect with community, and raise diabetes awareness around the world XX The European Association for the Study of Diabetes (EASD) 2025 Annual Meeting will feature major clinical trial results in type 2 diabetes (T2D), type 1 diabetes (T1D), obesity, several new clinical practice guidelines, and much more. The 61st annual EASD meeting will take place on September 15-19, 2025, in Vienna, Austria.   

Join experts in obesity, Robert Kushner, MD, Michael Knight, MD, and Amanda Velazquez, MD, as they discuss impactful communication for patients with obesity. Bob Kushner, MD  Amanda Velazquez, MB, DABOM Michael Knight, MD, MSHP, FACP, DABOM

Morse code transcription: vvv vvv Chappell Roan, Charli XCX and Doja Cat images among Music Photography Awards nominees Real Tarzann US influencer Mike Holston investigated over wild croc wrestling Repair Shop presenter Jay Blades pleads not guilty to rape Greenwich and Kent announce merger to form super university Police should stop recording non crime hate incidents, says watchdog Anti Islamic biker gang members run security at deadly Gaza aid sites Remains of missing Jordan Moray from Cwmbach found after six years Contactless card payments could become unlimited under new plans Ozempic maker Novo Nordisk to cut 9,000 jobs Mandelson expresses tremendous regret over Epstein friendship

The shock success of GLP-1 treatments for obesity carries massive implications for wealthy societies and manufacturers Novo Nordisk and Eli Lilly alike. In this week's Viewsroom podcast, Breakingviews columnists discuss how this would-be jackpot has companies running to keep up. Visit the Thomson Reuters Privacy Statement for information on our privacy and data protection practices. You may also visit megaphone.fm/adchoices to opt-out of targeted advertising. Learn more about your ad choices. Visit megaphone.fm/adchoices

In der heutigen Folge sprechen die Finanzjournalisten Nando Sommerfeldt und Holger Zschäpitz über das Tauziehen bei SAP, Kursgewinne bei Zara, einen Einbruch bei Primark und die Tierfutter-Ernüchterung. Außerdem geht es um Broadcom, Arm Holdings, Constellation Energy, Nvidia, Synopsys, Cadence Design Systems, Chewy, Alstom, Novo Nordisk, Inidtex, AB Foods, Microsoft, Amazon, Meta, Alphabet, Iren, Nebius, Coreweave, Service Now, Alibaba, WisdomTree Cloud Computing ETF (WKN: A2PQVE), First Trust Cloud Computing ETF (WKN: A2N9EF), Global X Cloud Computing  ETF (WKN: A2QPBV), Xtrackers Artificial Intelligence & Big Data ETF (WKN: A2N6LC), Affirm. Die Tickets zum Finance Summit am 17. September bekommt ihr 40 Euro günstiger – aber nur mit dem exklusiven Code AAA2025, der ihr unter dem folgenden Link eingeben müsst: https://veranstaltung.businessinsider.de/BN5aLV Außerdem könnt ihr unter diesem Link euer Depot hochladen – und mit etwas Glück wird kein Geringerer als Christian W. Röhl euer Depot beim Summit checken und optimieren. https://form.jotform.com/Product_Unit/formular-finance-summit-depot-check Wir freuen uns über Feedback an aaa@welt.de. Noch mehr "Alles auf Aktien" findet Ihr bei WELTplus und Apple Podcasts – inklusive aller Artikel der Hosts und AAA-Newsletter. Hier bei WELT: https://www.welt.de/podcasts/alles-auf-aktien/plus247399208/Boersen-Podcast-AAA-Bonus-Folgen-Jede-Woche-noch-mehr-Antworten-auf-Eure-Boersen-Fragen.html. Der Börsen-Podcast Disclaimer: Die im Podcast besprochenen Aktien und Fonds stellen keine spezifischen Kauf- oder Anlage-Empfehlungen dar. Die Moderatoren und der Verlag haften nicht für etwaige Verluste, die aufgrund der Umsetzung der Gedanken oder Ideen entstehen. Hörtipps: Für alle, die noch mehr wissen wollen: Holger Zschäpitz können Sie jede Woche im Finanz- und Wirtschaftspodcast "Deffner&Zschäpitz" hören. +++ Werbung +++ Du möchtest mehr über unsere Werbepartner erfahren? Hier findest du alle Infos & Rabatte! https://linktr.ee/alles_auf_aktien Impressum: https://www.welt.de/services/article7893735/Impressum.html Datenschutz: https://www.welt.de/services/article157550705/Datenschutzerklaerung-WELT-DIGITAL.html

Morse code transcription: vvv vvv Police should stop recording non crime hate incidents, says watchdog Ozempic maker Novo Nordisk to cut 9,000 jobs Repair Shop presenter Jay Blades pleads not guilty to rape Real Tarzann US influencer Mike Holston investigated over wild croc wrestling Anti Islamic biker gang members run security at deadly Gaza aid sites Greenwich and Kent announce merger to form super university Chappell Roan, Charli XCX and Doja Cat images among Music Photography Awards nominees Remains of missing Jordan Moray from Cwmbach found after six years Contactless card payments could become unlimited under new plans Mandelson expresses tremendous regret over Epstein friendship

Morse code transcription: vvv vvv Greenwich and Kent announce merger to form super university Mandelson expresses tremendous regret over Epstein friendship Anti Islamic biker gang members run security at deadly Gaza aid sites Chappell Roan, Charli XCX and Doja Cat images among Music Photography Awards nominees Police should stop recording non crime hate incidents, says watchdog Ozempic maker Novo Nordisk to cut 9,000 jobs Repair Shop presenter Jay Blades pleads not guilty to rape Contactless card payments could become unlimited under new plans Remains of missing Jordan Moray from Cwmbach found after six years Real Tarzann US influencer Mike Holston investigated over wild croc wrestling

Morse code transcription: vvv vvv Mandelson expresses tremendous regret over Epstein friendship Greenwich and Kent announce merger to form super university Anti Islamic biker gang members run security at deadly Gaza aid sites Remains of missing Jordan Moray from Cwmbach found after six years Police should stop recording non crime hate incidents, says watchdog Chappell Roan, Charli XCX and Doja Cat images among Music Photography Awards nominees Ozempic maker Novo Nordisk to cut 9,000 jobs Real Tarzann US influencer Mike Holston investigated over wild croc wrestling Repair Shop presenter Jay Blades pleads not guilty to rape Contactless card payments could become unlimited under new plans

Ce matin, on parle d'un sujet central : l'inflation. Pourquoi ? Parce qu'elle est la clé de tout.Aux US, le dernier rapport sur l'emploi et le PPI montrent un ralentissement, mais la pression des prix sous-jacents reste là. Résultat : le marché price une baisse de taux dès septembre, et jusqu'à 75 points de base d'ici fin d'année.Conséquence directe : obligations US à 10 ans au plus bas depuis avril, dollar plus faible, et l'or sur un nouveau record.En Europe, la tension se déplace : les coûts d'emprunt de la France passent au-dessus de ceux de l'Italie, reflet de la défiance politique et budgétaire.Côté entreprises : Oracle explose de +43% en une séance (contrats cloud/IA massifs), Anglo American fusionne avec Teck Resources (53 Md$), Novo Nordisk annonce 9 000 suppressions d'emplois, et Inditex déçoit sur ses ventes.Dans la tech US, le cloud et l'IA redéfinissent les positions : Oracle, Nvidia, Broadcom, Tesla… chacun scruté à la loupe.En cryptos, prudence : sentiment de peur, vols de 3 Md$ au 1er semestre, mais institutionnels toujours plus présents (Nasdaq tokenisation, Binance-Franklin Templeton).Et côté politique : Trump veut des tarifs à 100% contre Chine & Inde, Bayrou chute en France, les spreads français/italiens deviennent le symbole du risque politique européen.

A.M. Edition for Sept. 10. Russian drones went further into NATO-territory than ever before during the Ukraine war, with Polish Prime Minister Donald Tusk calling the attack a large-scale provocation. WSJ editor Dan Michaels details the allied response and what we know so far. Plus, weight-loss drug giant Novo Nordisk slashes thousands of jobs. And, WSJ's Hannah Erin Lang details Robinhood's plans to launch a social-media platform, in a bid to get traders off Reddit. Caitlin McCabe hosts. Sign up for the WSJ's free What's News newsletter. Learn more about your ad choices. Visit megaphone.fm/adchoices

In this episode, Scott Becker covers market gains, Oracle's AI cloud surge, Wall Street's outlook, Novo Nordisk job cuts, and Amazon's AI edge.

Plus: A federal judge blocks President Trump from removing Lisa Cook from the Federal Reserve Board. And, Ozempic-maker Novo Nordisk cuts 9,000 jobs as weigh-loss drug competition bites. Kate Bullivant hosts. Sign up for WSJ's free What's News newsletter. Learn more about your ad choices. Visit megaphone.fm/adchoices

Today we feature Saxo equity strategist Ruben Dalfovo helping break down what is driving the moon-shot in Oracle shares after the company blew the doors off of expectations with forward cloud infrastructure bookings in its earnings call after the close yesterday. We also look at the Klarna IPO forthcoming today, Novo Nordisk shares rallying on the company's cost reductions, the latest in geopolitics, macro and currencies and much more. Hosting today's pod is Saxo Global Head of Macro Strategy John J. Hardy. Links discussed on the podcast and our Chart of the Day can be found on the John J. Hardy substack (with a one- to two-hour delay from the time of the podcast release). Read daily in-depth market updates from the Saxo Market Call and the Saxo Strategy Team here. Please reach out to us at marketcall@saxobank.com for feedback and questions. Click here to open an account with Saxo. Intro and outro music by AShamaluevMusic

In her annual State of the Union address, European Commission president Ursula von der Leyen has told the European Parliament it needs to regain its independence and bolster its defence capabilities in a 'hostile' world. Also, Danish company Novo Nordisk, the maker of weight-loss drugs Wegovy and Ozempic, has announced plans to cut 9,000 jobs. And the British horse racing industry has gone on strike for the first time ever, in protest at proposed tax rises on bets placed on the sport. You can contact us on WhatsApp or send us a voicenote: +44 330 678 3033.

Analysts left ‘kind of in shock' after Oracle reports eye-popping cloud demand numbers, sending the stock soaring and making Larry Ellison the world's richest man. Buy now, pay later service Klarna starts trading after delaying its IPO.  Plus, Novo Nordisk announces big job cuts. 

It would seem that investors are all in on Buy Now - Pay Later and that story kicks us off today.  This is the Business News Headlines for Wednesday the 10th day of September, thanks for listening.  In other news, producer prices actually fell a bit last month and what that means. Danish drug maker Novo Nordisk is cutting thousands of workers. Embattled Fed Governor Lisa Cook can keep her job…for now.  The fallout from that massive number of jobs that were not created is getting a hard look. The raid was about illegal vaping products and we'll tell you about it.  We'll check the numbers in The Wall Street Report and even more news today about the ongoing saga at Cracker Barrel.  Let's go! Thanks for listening! The award winning Insight on Business the News Hour with Michael Libbie is the only weekday business news podcast in the Midwest. The national, regional and some local business news along with long-form business interviews can be heard Monday - Friday. You can subscribe on  PlayerFM, Podbean, iTunes, Spotify, Stitcher or TuneIn Radio. And you can catch The Business News Hour Week in Review each Sunday Noon Central on News/Talk 1540 KXEL. The Business News Hour is a production of Insight Advertising, Marketing & Communications. You can follow us on Twitter @IoB_NewsHour...and on Threads @Insight_On_Business.

Nel discorso sullo Stato dell’Unione a Strasburgo, Ursula von der Leyen ha invocato maggiore autonomia europea in difesa, energia, tecnologia ed economia. Sull’Ucraina, proposta l’utilizzazione dei fondi russi congelati per prestiti a Kiev e un’alleanza per la produzione di droni (6 miliardi di euro). Sul fronte economico, annunciata una tabella di marcia per rafforzare il mercato unico entro il 2028, liberalizzando servizi, energia e telecomunicazioni. In materia ambientale, confermata la riduzione del 90% delle emissioni al 2040, con il futuro dell’auto orientato all’elettrico, ma restano dubbi sui costi. L’industria automobilistica europea, riunita a Monaco, chiede più flessibilità normativa, appello sostenuto anche dal cancelliere tedesco Merz. Ne parliamo con Adriana Cerretelli, editorialista Sole 24 Ore Bruxelles.Macron nomina nuovo premier il giovane LecornuEmmanuel Macron ha nominato premier Sébastien Lecornu, 39 anni, ministro delle Forze Armate e suo fedelissimo, dopo le dimissioni di François Bayrou. Lecornu eredita un contesto complicato: una manovra da 43,8 miliardi, un voto di sfiducia e una maggioranza frammentata. Dovrà costruire una coalizione stabile, con LFI che continua a chiedere la destituzione di Macron. La nomina segna anche una rivincita politica del presidente, che aveva scelto Lecornu già a dicembre. Intanto, proteste in strada e oltre 100 arresti, soprattutto a Parigi. Il commento è di Marc Lazar, Presidente della School of Government dell'Università Luiss.Istat, boom prezzi alimentari: +30% rispetto al 2019 Secondo l’Istat, a luglio 2025 i prezzi degli alimentari in Italia sono saliti del 30,1% rispetto al 2019, meno della media UE (+39,2%). Germania e Spagna hanno registrato rincari maggiori, mentre la Francia un aumento più contenuto (+27,5%). L’aumento dei beni alimentari (88,5% del “carrello della spesa”) ha allargato il divario con l’inflazione generale, influenzata anche dai prezzi energetici: a agosto il differenziale ha raggiunto 1,9 punti percentuali. Interviene Massimo Baldini, docente di Scienza delle Finanze presso l' Università di Modena e Reggio Emilia.Novo Nordisk taglierà 9.000 posti di lavoro. Nel 2025 stime profitti riviste tre volte. Pesa la concorrenzaDopo aver perso il 60% in Borsa e 170 miliardi di euro di capitalizzazione, Novo Nordisk annuncia 9.000 tagli (11% della forza lavoro) per risparmiare 1,3 miliardi di dollari entro il 2026. Riviste al ribasso per la terza volta le stime di crescita dei profitti, ora previste tra il 4% e il 10% contro il 27% stimato a inizio anno. L’azienda punta a riorganizzarsi per concentrarsi su diabete e obesità, ma soffre la concorrenza di Eli Lilly, che domina il mercato Usa. Tentativi legali contro copie non autorizzate del semaglutide non hanno fermato la perdita di quote. Il nuovo Ceo Doustdar parla di decisioni difficili ma necessarie per il futuro. Il commento è affidato a Biagio Simonetta, Il Sole 24 Ore.

Der er masser at se til for de danske detailinvestorer. Nogle af deres favoritselskaber - Bavarian Nordic, Novo Nordisk og Ørsted - er i ilden. Spørgsmålet er, hvordan man skal forholde sig til købstilbud, kapitaludvidelse og en voldsom kursnedtur. Det diskuterer Millionærklubben denne onsdag formiddag, hvor vi også tager temperaturen på de globale finansmarkeder. Med i studiet er Michael Friis Jørgensen fra HC Andersen Capital, samt direktør i Dansk Aktionærforening Mikael Bak. Med over telefonen får vi Jonas Pallesen, der er med i Millionærklubbens Aktiespil, og som vandt aktiespillet hos Dagbladet Børsen i 2024. Vært: Adam Geil See omnystudio.com/listener for privacy information.

Israel fires missiles at Hamas' leadership targets in Qatar, undermining hopes of a ceasefire in Gaza and drawing the ire of President Trump. Emmanuel Macron appoints defence minister Sebastien Lecornu as his next prime minister. Lecornu is now tasked with passing the government's reform agenda as well as a its fiscal package. A U.S. judge has temporarily prevented President Trump from firing Fed governor Lisa Cook over alleged mortgage improprieties, saying that the claims of fraud before she was appointed would not constitute grounds for removal. And in pharma news, drug maker Novo Nordisk is set to slash up to 9,000 jobs on the back of weaker sales and strong competition Stateside. See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

In this episode, Scott Becker covers market gains, Oracle's AI cloud surge, Wall Street's outlook, Novo Nordisk job cuts, and Amazon's AI edge.

Protests gripped France nationwide on Wednesday as the newly appointed prime minister, Sébastien Lecornu, assumed office. Protesters demonstrated their anger at potentially massive spending cuts, as opposition lawmakers defended their counter-proposals to tackle France's debt and deficit. So what's in their plans? Plus, Danish pharma giant Novo Nordisk announces a plan to cut 9,000 jobs as the maker of Wegovy and Ozempic struggles to turn its fortunes around. 

Novo Nordisk, la empresa productora del Ozempic, va a reajustar su plantilla con 9.000 despidos. El objetivo: adaptar su estrategia a la competencia de otros productos para la diabetes y, en general, a los cambios del mercado. ¿Tiene margen para seguir creciendo? Lo analizamos en Hora 25 de los Negocios. 

Miguel Méndez, Analista independiente comenta la situación de los valores bursátiles. Inditex es protagonista en el día de hoy con su presentación de resultados, y aunque el título sube, “las cuentas no arrojan un crecimiento deslumbrante” asegura. Aún así, Méndez confía que los resultados actúen como catalizador para que el valor recupere niveles y se acerque a los 49 euros. El experto financiero también ha analizado el sector farmacéutico con Novo Nordisk y Eli Lilly, que no atraviesan un momento especialmente positivo. Es por ello que Méndez no ve motivos suficientes para tomar posiciones en estas compañías. Mientras tanto, Lululemon, atraviesa dificultades causadas por los aranceles, lo que prolonga el sufrimiento bursátil. No obstante, apunta que “a los precios actuales la compañía ofrece potencial” y, a medio plazo, se inclina por mantenerla en cartera. Por último, muestra su confianza en Lotus Bakeries, valor en el que mantiene expectativas de que alcance los 10.000 puntos, con un nivel clave en los 9.140. “Me sigue gustando, creo en la empresa”, afirma.

La chronique du jour n'a pas été bloquée ce matin. Parmi les autres choses qui ne seront pas bloquées, je peux citer la hausse d'Oracle, la sortie de l'iPhone 17 Air, la nomination d'un nouveau Premier ministre et les discussions entre les Etats-Unis et l'Inde. En revanche, ont été bloqués les drones russes en Pologne, les embauches chez Novo Nordisk et la destitution de Lisa Cook.

(02:00): LA kritiserer for at dække for lidt politik og for meget "proces-fnidder", men kan ikke. Medvirkende: Sólbjørg Jakobsen, politisk ordfører for Liberal Alliance. (10:00): Gentagne krænkelser af Polens luftrum i nat. Medvirkende: Peter Viggo Jakobsen, lektor ved Forsvarsakademiet. (30:00): Novo Nordisk fyrer 9000 medarbejdere. Medvirkende: Thomas Bernt Henriksen, erhvervskommentator på Berlingske. (41:00): Ordfører for Socialdemokratiet: Vi skal handle på kvindedrab nu! Medvirkende: Gunvor Wibroe, MF Socialdemokratiet Værter: Anne Philipsen & Nicolai Dandanell. See omnystudio.com/listener for privacy information.

Dagens vigtigste nyheder på 15 minutter. Det polske luftrum blev i nat krænket i en grad, at Det Nordatlantiske Råd skal indkaldes for at tale om, hvordan der skal reageres. Den polske premierminister taler om russiske droner og provokationer i stor skala. Novo Nordisk vil skære 9.000 stillinger væk. 5.000 af dem skal findes i Danmark. Medicinproducenten varsler en af de største sparerunder i dansk erhvervshistorie. Presset på Israel skal have et nøk mere på grund af krigen i Gaza. Europakommissionens formand vil sætte støtten til Israel på pause og indføre sanktioner. Vært: Maria Dohn.

Welcome to Ozempic Weightloss Unlocked. Today we dive into the latest headlines, research, controversies, and the practical realities of Ozempic, a medication originally crafted for type two diabetes that has rocketed into the spotlight for its weight-loss effects.Ozempic, with the active ingredient semaglutide, was approved in the United States in December 2017 to help manage blood sugar in people living with type two diabetes. However, it soon became widely prescribed off-label for weight loss, a trend that only accelerated after the higher-dose version, branded as Wegovy, received federal approval in 2021. According to the Lawsuit Information Center, Ozempic works by mimicking a hormone called glucagon-like peptide 1, helping regulate blood sugar and appetite. Many people using it experience reduced appetite and significant weight reduction.While its popularity continues to grow, so does scientific understanding. A 2025 study presented at the European Society of Cardiology conference revealed that Swiss patients with type two diabetes using oral semaglutide experienced clinically significant drops in both blood sugar and body weight. GlobalData reports that no new safety risks were identified in that trial, supporting ongoing confidence among healthcare professionals.But for those interested only in weight loss, it is not all smooth sailing. Ozempic carries a range of potential side effects. According to King Law, hundreds of lawsuits have been filed in the last year, with plaintiffs claiming they suffered severe complications such as gastroparesis, intestinal blockages, blood clots, and even hair loss. A study published this August found that women on Ozempic experienced twice the rate of hair loss as women who were not taking the drug, while men saw their risk climb by more than half.The United States Food and Drug Administration updated Ozempic's packaging earlier this year to warn about the risk of pancreatitis and severe kidney injuries, including potentially fatal outcomes linked to dehydration from vomiting and diarrhea. The label changes were driven by new clinical trial data and reinforce the importance of medical supervision when using these drugs.Shortages, once a common concern, have eased. The Food and Drug Administration officially took Ozempic off the drug shortage list in February after Novo Nordisk provided reassurance about inventory and supply. That move, however, sparked legal challenges from compounders competing in the market.Unfortunately, enthusiasm for rapid weight loss has also created a black market for Ozempic and similar drugs. The Food and Drug Administration cautions against using compounded or counterfeit versions, which have not undergone review for safety or effectiveness. Some of these unregulated products might be contaminated, mislabeled, or dangerously dosed. Always fill your prescriptions through a licensed pharmacy.For listeners interested in alternatives, exciting research is underway. Purdue University food scientists are investigating foods and supplements that naturally stimulate GLP-1, the hormone Ozempic is designed to mimic. While these approaches will not produce the dramatic weight loss seen with medication, they may help those seeking more natural solutions—especially if someone discontinues their prescription and needs help maintaining a healthy weight.So, where does Ozempic stand today? We have a medication achieving strong results for blood sugar control and weight loss, but one that comes with a profile of side effects still being researched, legal actions underscoring patient concerns, and increased focus on responsible, safe prescribing.Thank you for tuning in to Ozempic Weightloss Unlocked. For more news, insights, and emerging research on the evolving world of weight loss and metabolic health, be sure to subscribe. This has been a quiet please production, for more check out quiet please dot ai. Some great Deals https://amzn.to/49SJ3QsFor more check out http://www.quietplease.ai

Derek and Edgi share four safe dividend stocks for September ,Accenture, Fuchs Petrolub, Canadian Natural Resources, and Munich Re. They also cover market news on Sanofi, Novo Nordisk, and T. Rowe Price, discuss dividend hikes, and tackle listener questions on gifting stocks, building a five-stock portfolio, and the dividend growth vs. high yield debate.

In der heutigen Folge sprechen die Finanzjournalisten Lea Oetjen und Philipp Vetter über Broadcom, Analysten-Aufwind für Heidelberg Materials und JPMorgans Deutschland-Angriff. Außerdem geht es um Siemens Energy, RWE, Commerzbank, ProSiebenSat.1, RTL, Micron Technology, Amazon, Opendoor Technologies, Alphabet, JPMorgan, BMW, E.on, EnBW, GE Vernova, Bitcoin, Solana, Ethereum, Teamviewer, Cancom, Salzgitter, Volkswagen, Mercedes-Benz, TUI, Aurubis, Puma, Novo Nordisk, Vonovia, Krones, Bell Food Group, Bucher Industries, Haier Smart Home, Baidu, iShares MSCI World Energy Sector (WKN: A2PHCF), Amundi Stoxx 600 Energy ESG ETF (WKN: LYX02P). Die Tickets zum Finance Summit am 17. September bekommt ihr 40 Euro günstiger – aber nur mit dem exklusiven Code AAA2025, der ihr unter dem folgenden Link eingeben müsst: https://veranstaltung.businessinsider.de/BN5aLV Außerdem könnt ihr unter diesem Link euer Depot hochladen – und mit etwas Glück wird kein Geringerer als Christian W. Röhl euer Depot beim Summit checken und optimieren. https://form.jotform.com/Product_Unit/formular-finance-summit-depot-check Wir freuen uns über Feedback an aaa@welt.de. Noch mehr "Alles auf Aktien" findet Ihr bei WELTplus und Apple Podcasts – inklusive aller Artikel der Hosts und AAA-Newsletter. Hier bei WELT: https://www.welt.de/podcasts/alles-auf-aktien/plus247399208/Boersen-Podcast-AAA-Bonus-Folgen-Jede-Woche-noch-mehr-Antworten-auf-Eure-Boersen-Fragen.html. Der Börsen-Podcast Disclaimer: Die im Podcast besprochenen Aktien und Fonds stellen keine spezifischen Kauf- oder Anlage-Empfehlungen dar. Die Moderatoren und der Verlag haften nicht für etwaige Verluste, die aufgrund der Umsetzung der Gedanken oder Ideen entstehen. Hörtipps: Für alle, die noch mehr wissen wollen: Holger Zschäpitz können Sie jede Woche im Finanz- und Wirtschaftspodcast "Deffner&Zschäpitz" hören. +++ Werbung +++ Du möchtest mehr über unsere Werbepartner erfahren? Hier findest du alle Infos & Rabatte! https://linktr.ee/alles_auf_aktien Impressum: https://www.welt.de/services/article7893735/Impressum.html Datenschutz: https://www.welt.de/services/article157550705/Datenschutzerklaerung-WELT-DIGITAL.html

No sétimo episódio do programa CEO's Talk Show, o publicitário Nizan Guanaes entrevista Isabella Wanderley, da Novo Nordisk. A primeira temporada do projeto audiovisual de Meio & Mensagem e da agência California, gravada no Auditório Ibirapuera, em São Paulo, contempla sete entrevistas com presidentes de grandes empresas. O CEO's Talk Show conta com o apoio da Eletromidia, Samsung Ads e Urbia.

Ørsted ser ud til at få opbakning til redningsplan, men analytikere advarer om at købe aktien. Eksperter råder til at tage tabet fra fald i Novo Nordisk-aktien. Hver femte store, private virksomhed i Danmark er udfordret af dårlig ledelse. Brian Mikkelsen kræver lavere erhvervsskatter. Russisk økonomi halter men er meget langt fra kollaps. Google flyver til vejrs efter juridisk afgørelse. Vært: Lasse Ladefoged (lasse.ladefoged@borsen.dk)  

Paco Pérez, analista independiente, repasa la actualidad de los mercados en el consultorio de bolsa y destaca que septiembre suele ser un mes marcado por la volatilidad. “El gráfico del Ibex está siendo muy fiel a lo que es septiembre: un mes con mucho ruido por tradición, pero que convierte ese ruido en oportunidades”, afirma. En cuanto a los activos refugio, Pérez explica que “el oro vuelve a estar en máximos de varios años, tras un primer impulso alcista, y lo lógico ahora es que tenga un descanso”. Sobre el bitcoin, advierte que está en fase correctiva y prevé que esa corrección sea análoga a la de los índices bursátiles. En lo sectorial, muestra confianza en las farmacéuticas europeas, especialmente en aquellas menos expuestas a Estados Unidos, debido a los aranceles. “Podemos tener grandes oportunidades en una gran compañía como Novo Nordisk”, señala.

Nos fijamos hoy en Porsche, Sartorius, Sanofi o Novo Nordisk con Xavier Brun, responsable de RV europea de Trea AM.

Alessandro Fusacchia"Festival del Pensare Contemporaneo"Vite SvelatePiacenza, 11>14 Settembre 2025www.pensarecontemporaneo.itTorna a Piacenza il Festival del Pensare Contemporaneo per la sua terza edizione da giovedì 11 a domenica 14 settembre 2025. L'obiettivo del Festival è guidare il pubblico alla scoperta del sé, individuale e collettivo, per riaffermare la propria presenza nel mondo, attraverso visioni, dialoghi e sfide stimolanti. Il tema di quest'anno, “Vite Svelate. Esporsi/Scoprirsi”, continua il viaggio iniziato con “Vivere la Meraviglia”, guidandoci dallo stupore alla scoperta più intima della vita.Promosso da Rete Cultura Piacenza, il Festival è curato per il terzo anno da Alessandro Fusacchia, con la direzione filosofica di Andrea Colamedici e Maura Gancitano di Tlon.Il tema “Vite Svelate” invita a un'introspezione profonda, esplorando la vulnerabilità non come debolezza, ma come forza e resistenza in un'epoca che ci vuole invulnerabili. Il Festival porta a Piacenza voci stimolanti, ponendo un focus urgente sulle nuove generazioni: il loro disagio esistenziale è visto non come un problema da risolvere, ma come un punto di partenza per nuove forme di consapevolezza e cura.La musica inaugurerà questa nuova edizione del Festival del Pensare Contemporaneo attraverso i concerti filosofici previsti per giovedì 11 settembre alle 18:30 in piazza Cavalli. Si esibiranno sul palco per una serata di musica e parole: N.A.I.P., Nayt, Anna Castiglia, Giulia Mei, Francesco Bianconi dei Baustelle ed Emma Nolde. Vite Svelate proseguirà poi fino a domenica 14 settembre con 80 eventi in programma, molti di questi in contemporanea, con fino a cinque appuntamenti in parallelo, in 14 location diffuse. Riconfermato anche il Premio Internazionale “Pensare Contemporaneo”, istituito dai promotori del Festival e diretto a personalità di rilievo che grazie agli studi, le opere e la divulgazione hanno saputo influenzare in maniera significativa a livello internazionale il pensiero e la visione sulla società contemporanea. Quest'anno la commissione premierà lo scrittore cileno Benjamín Labatut, autore di libri come Maniac (Adelphi, 2023) e Quando abbiamo smesso di capire il mondo (Adelphi, 2021). Labatut terrà una lectio su “Vite Svelate” durante la cerimonia di chiusura e di assegnazione del premio domenica 14 settembre alle 21 al Palazzo Gotico. Per la terza edizione, il Festival ha confermato alcuni partenariati, tra questi, quello con il Forum Disuguaglianze Diversità, per realizzare appuntamenti congiunti anche sull'Europa e tra le università: l'Università Cattolica del Sacro Cuore, il Politecnico di Milano, l'Università degli studi di Parma e il Conservatorio Nicolini di Piacenza. Torna, inoltre, la proiezione internazionale del Festival, grazie ad un accordo strategico con il think tank brussellese Friends of Europe.Novità di quest'anno è il coinvolgimento della Fondazione Una Nessuna Centomila, di cui Fiorella Mannoia è presidente onoraria, che in sinergia con il Comune di Piacenza avvierà un dialogo con i centri antiviolenza del territorio.La realizzazione del Festival del Pensare contemporaneo è resa possibile grazie a un gruppo di sponsor e mecenati importanti, di rilievo nazionale oltre che locale, a partire dal main sponsor Banca Generali, seguito da Coop San Martino, Gas Sales, Confindustria Piacenza, Consorzio di Bonifica Piacenza, Conad Centro Nord, ALS, Arcadia, ENI, Moncler, CA Indosuez, Poste Italiane, Douglas Chero, Novo Nordisk e Trenitalia in qualità di Official green carrier, oltre a numerosi altri sostenitori.Parteciperanno al Festival: il poeta e paesologo Franco Arminio con suo figlio Livio Arminio, la scrittrice Chiara Barzini, la giornalista e divulgatrice scientifica Silvia Bencivelli, il cantautore e frontman del gruppo musicale Baustelle Francesco Bianconi, lo scrittore Enrico Brizzi, la scrittrice Teresa Ciabatti, la sociologa Francesca Coin, lo scrittore Nicola H. Cosentino, l'economista e ex senatore Carlo Cottarelli,  l'attivista Marina Cuollo, la giornalista e scrittrice Concita De Gregorio, il sociologo Derrick De Kerckhove, lo scrittore Paolo Di Paolo, il graphic designer Riccardo Falcinelli, il filosofo Maurizio Ferraris, il giornalista James Fontanella-Khan, l'architetto e designer Massimiliano Fuksas, la scrittrice Lisa Ginzburg, il direttore generale dell'ICCROM Aruna Gujral, la pubblico ministero Disa Jironet, l'esploratore e scrittore Erling Kagge, lo scrittore Benjamín Labatut, lo scrittore Björn Larsson, lo scrittore Vincenzo Latronico, lo storico e sociologo Marc Lazar, lo psichiatra e saggista Vittorio Lingiardi, il Cross Cultural Entrepreneur and Strategist Liel Maghen, l'ex membro del Parlamento europeo Magid Magid, la filosofa Claire Marin, la scrittrice Melania Mazzucco, la direttrice del Cimitero Acattolico Yvonne Mazurek, l'artista musicale Giulia Mei, il giornalista Luca Misculin, il musicista e compositore N.A.I.P., il rapper Nayt, l'artista musicale Emma Nolde, la scrittrice Valeria Parrella, lo scrittore Alcide Pierantozzi, il violinista e compositore Alessandro Quarta, il ballerino Giacomo Rovero, la caporedattrice del Kyiv Independent Olga Rudenko, la giornalista Cecilia Sala, lo scrittore Antonio Scurati, il consulente per gli Affari istituzionali e della Pubblica amministrazione Vincenzo Sofo, lo storico dell'arte e divulgatore Jacopo Veneziani. IL POSTO DELLE PAROLEascoltare fa pensarewww.ilpostodelleparole.itDiventa un supporter di questo podcast: https://www.spreaker.com/podcast/il-posto-delle-parole--1487855/support.

Read the full transcript here. How do we distinguish correlation from causation in organizational success? How common is it to mistake luck or data mining for genuine effects in research findings? What are the challenges in interpreting ESG (Environmental, Social, Governance) criteria? Why is governance considered distinct from environmental and social impact? How should uncertainty in climate science affect our policy choices? Are regulation and free markets really at odds, or can they be mutually reinforcing? How does economic growth generated by markets fund social programs and environmental protection? How does “publish or perish” culture shape scientific research and incentives? What psychological and neuroscientific evidence explains our tendency toward confirmation bias? Will LLMs exacerbate or mitigate cognitive traps? How do biases shape popular narratives about diversity and corporate purpose? How can we balance vivid stories with rigorous data to better understand the world?Alex Edmans FBA FAcSS is Professor of Finance at London Business School. Alex has a PhD from MIT as a Fulbright Scholar, was previously a tenured professor at Wharton, and an investment banker at Morgan Stanley. He serves as non-executive director of the Investor Forum and on Morgan Stanley's Institute for Sustainable Investing Advisory Board, Novo Nordisk's Sustainability Advisory Council, and Royal London Asset Management's Responsible Investment Advisory Committee. He is a Fellow of the British Academy and a Fellow of the Academy of Social Sciences.Links:Alex's TEDx TalkAlex's books: May Contain Lies and Grow The PieAlex's BlogA double bind in collective learning (article) StaffSpencer Greenberg — Host / DirectorJosh Castle — ProducerRyan Kessler — Audio EngineerUri Bram — FactotumWeAmplify — TranscriptionistsIgor Scaldini — Marketing ConsultantMusicBroke for FreeJosh WoodwardLee RosevereQuiet Music for Tiny Robotswowamusiczapsplat.comAffiliatesClearer ThinkingGuidedTrackMind EasePositlyUpLift[Read more]

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world. Novo Nordisk's drug Wegovy has successfully reduced cardiovascular risk by 57% compared to tirzepatide. Eli Lilly has terminated two mid-stage trials for a second obesity asset, while Vertex Pharmaceuticals and Enlaza Therapeutics have formed a potential $2 billion partnership to develop drugs for autoimmune diseases. Biogen and Eisai have received FDA approval for the subcutaneous maintenance formulation of Leqvembi. Arrowhead Pharmaceuticals has secured a commitment of up to $2 billion from Novartis for an siRNA Parkinson's program. The FDA's new radiopharma guidance is expected to accelerate the space, and Teva has launched the first generic version of Novo Nordisk's obesity drug Saxenda. The pharmaceutical industry is navigating uncertainty during turbulent times, with companies focusing on innovation and new partnerships to drive progress.The FDA has issued new radiopharma guidance, which former FDA Commissioner Stephen Hahn believes is crucial for cancer therapy. Despite recent investments in radiopharmaceutical therapeutics by big pharma, the FDA's approval of updated COVID-19 vaccines with restrictions contradicts the medical freedom promised by health secretary Robert F. Kennedy Jr. Rare diseases secured four FDA firsts in August, including a win for Novo Nordisk's glp-1 drug WeGovy. Investment in new ALS therapies signals progress after setbacks, with new biotechs and collaborative initiatives showing promise at Bio2025. Other news includes the closure of Appia, Senate summons of Kennedy, updates on COVID-19 vaccines, and Lilly's obesity pill heading to the FDA. Thank you for listening to Pharma and Biotech daily.

We returned from the Labor Day holiday to a spate of intriguing deals, including two that could surpass $2 billion: Vertex's new pact with Enlaza for autoimmune disease—which the Casgevy maker hopes could ease conditioning for the sickle cell/beta thalassemia gene therapy—and Novartis' agreement with Arrowhead for neurodegenerative diseases such as Parkinson's.  But as we look ahead, Thursday's Senate Finance Committee will be the focus this week, as Health and Human Services Secretary Robert F. Kennedy Jr. will answer questions after the ousting of CDC Director Susan Monarez. Her departure is reportedly linked to changes to the regulation of COVID-19 vaccines, for which the FDA last week issued restricted approvals to Moderna, Pfizer/BioNTech and Novavax and rescinded the emergency use authorizations. The next ACIP meeting—where COVID-19 vaccines will be on the agenda—is set for Sept. 18 and 19.   In the weight loss arena, Novo Nordisk presented results from a real-world study this weekend at the European Society of Cardiology Congress in Madrid showing that Wegovy cut the risk of heart attack, stroke or death by 57% compared to Eli Lilly's tirzepatide in people with obesity and cardiovascular disease. The company also continues to throw money into the space, last week inking a $550 million deal with Replicate for RNA-based treatments for obesity and diabetes. Meanwhile, Lilly is dropping studies of one oral obesity candidate as another nears a regulatory filing. Finally, the FDA greenlit the first GLP-1 generic for obesity.   We also discuss reactions to the FDA's new guidance on radiopharma drug development, four recent approvals for rare diseases, and everything you ever wanted to know about SPACs. 

This week's Market Mondays is packed with high-level investing questions and timely market insights. We break down which five companies could thrive under a Trump administration, discuss whether Nvidia has a revenue concentration problem, and share advice for investors earning $50K–$100K per year on how to balance stocks, bonds, and real estate. We also dive into how to calculate intrinsic value—Ben Graham style, Warren Buffett style, or your own strategy—and what to actually do when your 5–10 year holding period is up.We also explore September 2025 market outlooks, Morgan Stanley's latest stock picks, and Alibaba's surprising surge after reports it may challenge Nvidia in the AI chip space. From fixed income products like MSTY and NVDY to the crypto markets hovering at key Fibonacci levels, we break down what's holding Bitcoin and ETH back, and how investors should be positioning in a historically tricky month. Plus, we play a round of “Don't Love, Marry, Kill” with Charter Communications, Hormel Foods, and Keurig Dr Pepper.Finally, we dig into the brewing legal storm around Novo Nordisk and Eli Lilly, facing over 2,000 lawsuits tied to Ozempic and similar drugs, with potential liability estimated in the billions. Is this the “death of Novo Nordisk,” or just another chapter in the evolving GLP-1 drug story? Tune in for sharp analysis, real strategies, and answers to the questions you've been asking all week.#MarketMondays #Investing #Stocks #Crypto #AI #Trump #Nvidia #Ozempic #WealthBuilding #FinancialLiteracyOur Sponsors:* Check out PNC Bank: https://www.pnc.com* Check out Square: https://square.com/go/eylSupport this podcast at — https://redcircle.com/marketmondays/donationsAdvertising Inquiries: https://redcircle.com/brandsPrivacy & Opt-Out: https://redcircle.com/privacy

Hvordan slår man markedet gennem 20 år? Det ved dagens gæst i Millionærklubben en hel del om, for i mere end to årtier har han i snit leveret tæt på 19% årligt i afkast, altså langt mere end de ca. 9%, som verdensindekset har præsteret i samme periode. Heldigvis deler han gerne opskriften, så lyt med, når investor og indehaver af Jackson FamilieInvest, Thorleif Jackson, beskriver vejen til høj vækst i porteføljen. I studiet tager teknisk analytiker Lars Persson fra Aktierådet lytterne en tur ud på dagens marked, hvor bl.a. Novo Nordisk endnu engang er i fokus. Og sidst i udsendelsen kan du møde Søren Bentzen, der er kommet særdeles godt fra start i Millionærklubbens aktiespil. Vært: Bodil Johanne GantzelSee omnystudio.com/listener for privacy information.

Novo Nordisk præsenterer stærke resultater for Wegovy til hjertepatienter. Novo-ansattes aktiegaver er tæt på at gå i 0. Onlinesupermarkedet Nemlig vil være profitable og billige. Hjemmearbejde på tilbagetog i finanssektoren viser undersøgelse. Grænser for topskat fastsat fra 2026. Xi, Putin og Modi mødtes i Shanghai. Vært: Lasse Ladefoged (lasse.ladefoged@borsen.dk)

With US markets shut for the Labor Day holiday, trading across the Northern Hemisphere was subdued. Still, Eurozone stocks closed higher on a defence boost, while European bond yields climbed ahead of a French confidence vote. Meanwhile, Novo Nordisk gained on optimism over heart disease treatments, and China’s factory activity expanded at its fastest pace in five months. In commodities, oil prices firmed ahead of this week’s OPEC meeting, while gold hovered near a four-month high. Back home, Aussie shares are set to open slightly lower on Tuesday as investors brace for a data-heavy week. The content in this podcast is prepared, approved and distributed in Australia by Commonwealth Securities Limited ABN 60 067 254 399 AFSL 238814. The information does not take into account your objectives, financial situation or needs. Consider the appropriateness of the information before acting and if necessary, seek appropriate professional advice.See omnystudio.com/listener for privacy information.

Edwin Gonzalez shares his journey from a BioBuilder apprentice to becoming a lead scientific support specialist at Thermo Fisher by age 23, highlighting how hands-on experiences and mentorship shaped his career path.• Middle school science teacher sparked Edwin's interest in science through engaging projects and supportive environment• First in his family to pursue science, without STEM role models at home• Joined BioBuilder apprenticeship program in 2019 after learning about it from a classmate• Gained first hands-on lab experience learning aseptic technique, pipetting, PCR, and bacterial transformation• Worked on biodesign project to create a device detecting airborne allergens• BioBuilder experience helped him decide to major in biology at Suffolk University• Skills learned at BioBuilder created foundation that made college coursework easier• Landed first industry position at Novo Nordisk through connections from a LabCentral internship• Currently works at Thermo Fisher as a lead scientific support specialist• Role combines lab operations, facilities management and direct research support• Recommends exploring multiple aspects of biology to build a diverse toolkit of experiencesLearn more about BioBuilder's programs for students, educators, and industry professionals here

Oggi a Start parliamo dell'impatto sulla crescita della Danimarca delle difficoltà dell'azienda farmaceutica Novo Nordisk, poi di cosa vuol dire guerra ibrida nei paesi di Baltico e infine di una storia di innovazione e rispetto dell'ambiente che arriva da Trentino Alto Adige, Val di Non Learn more about your ad choices. Visit megaphone.fm/adchoices

It's In the News.. a look at the top headlines and stories in the diabetes community. This week's top stories: CRISPR modified cell transplant for type 1, risk of T1D if parent has a different type of diabetes, Metformin and the brain, oral GLP-1, and more! Find out more about Moms' Night Out  Please visit our Sponsors & Partners - they help make the show possible! Learn more about Gvoke Glucagon Gvoke HypoPen® (glucagon injection): Glucagon Injection For Very Low Blood Sugar (gvokeglucagon.com) Omnipod - Simplify Life Learn about Dexcom   Check out VIVI Cap to protect your insulin from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Twitter Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com  Reach out with questions or comments: info@diabetes-connections.com Episode transcription with links: Hello and welcome to Diabetes Connections In the News! I'm Stacey Simms and every other Friday I bring you a short episode with the top diabetes stories and headlines happening now. XX A 42-year-old man who has lived most of his life with type 1 diabetes has become the first human to receive a transplant of genetically modified insulin-producing cells. This marks the first pancreatic cell transplant in a human to sidestep the need for immunosuppressant drugs. “This is the most exciting moment of my scientific career,” says cell biologist Per-Ola Carlsson of Uppsala University in Sweden, who helped develop the procedure. The new treatment, he says, “opens the future possibility of treating not only diabetes but other autoimmune diseases.” This procedure uses the gene editing technique, CRISPR, to discourage the auto immune attack on the donor cells. Before the transplant, the participant had no measurable naturally produced insulin and was receiving daily doses of the hormone. But within four to 12 weeks following the transplant, his levels rose slightly on their own after meals—showing that the new beta cells were releasing some insulin in response to glucose. even though the new study is promising, it involved just one participant and is therefore preliminary. And longer-term monitoring is needed to confirm the therapy's safety before it can be offered to more people. She also notes that the injected cells produced only 7 percent of the insulin needed for a person to be fully independent of additional medication. The researchers supplied the recipient with insulin doses to maintain healthy blood sugar levels. While Herold thinks it's still too early to consider this approach for a cure, “these options are now here to change the disease in ways that have never been possible before,” he says. “There's tremendous hope.” https://www.scientificamerican.com/article/type-1-diabetes-patients-insulin-production-restored-with-new-cell/ XX   This one is interesting… a recent study shows that children of mothers with gestational diabetes or fathers with type 2 diabetes have higher chances of developing type 1 diabetes than kids whose parents do not have any type of diabetes. Specifically, the study found that children whose mothers had gestational diabetes during pregnancy were 94% more likely to develop type 1 diabetes compared to children of mothers without diabetes. Similarly, having a father with type 2 diabetes was linked to a 77% higher risk. The study also suggests a possible link between maternal type 2 diabetes and type 1 diabetes in children, although more data are needed to confirm whether the risk is real.   "What is interesting is that type 1 diabetes is a disease of lack of the hormone insulin while gestational diabetes and type 2 diabetes stem mostly from the body's resistance to the hormone. What may be happening is that genes, environments and behaviors that create insulin resistance may also, in some cases, trigger the immune reactions that lead to type 1 diabetes," adds Dr. Dasgupta. A 2019 meta-analysis by researchers at Soochow University in China found that gestational diabetes was linked to a 66% higher risk of type 1 diabetes in children. This new study, which includes more than twice as many studies, offers a robust synthesis of current evidence and shows the risk is even greater than previously estimated. It is also the first meta-analysis to examine the link between paternal type 2 diabetes and type 1 diabetes in offspring. "Several mechanisms may be at play. Families often share lifestyle and eating habits, which can raise the likelihood that children will be affected. But beyond that, high blood sugar levels may also cause biological changes in parents that could increase their children's risk of developing type 1 diabetes," explains Laura Rendon, co-first author of the study, who completed an MSc in experimental medicine at The Institute and, as someone living with type 1 diabetes herself, finds deep personal meaning in conducting this research. For instance, the authors suggest that high blood sugar during pregnancy may stress the fetus's insulin-producing beta cells, reducing their number at birth or making them more vulnerable to damage later in life. It may also trigger epigenetic changes—modifications to proteins and molecules attached to DNA—that increase the risk. Likewise, high blood sugar in fathers with type 2 diabetes may cause epigenetic changes in their sperm, potentially influencing their child's risk of developing type 1 diabetes. https://medicalxpress.com/news/2025-08-diabetes-children-linked-parents.html XX Can a CGM help you lose weight? The company Signos is banking on it – the just got FDA approval for their system, which uses the over the counter Dexcom Stelo. The claim here is that the system will help track how food choices, activity, stress and sleep can all affect metabolism. Signos also works in partnership with the digital nutrition counseling startup Nourish. It currently offers a quarterly subscription plan, including six CGM sensors, for $139 per month. And they tell you don't take any medical actions based on the app's output without consulting a physician. https://www.fiercebiotech.com/medtech/fda-clears-signos-over-counter-cgm-powered-weight-loss-app XX Good news for T1D1, a free mobile app that helps people calculate insulin doses, track daily data, and share insights with healthcare providers. After being pulled off the market with similar apps a few years ago, it's now back and FDA approved. Drew Mendelow created the app after his diagnosis at age 13. He came on the show last year and I'll link his story up in the show notes. Diabetes Center Berne provided the initial funding to support the T1D1 efforts to redesign the app per FDA standards.  Comerge AG , the registered manufacturer, enlisted a team of software engineers, regulatory experts, and design professionals to ensure T1D1 was FDA-ready. Dexcom graciously conducted the Human Factors study to ensure safety and accuracy.  ​ ​T1D1 is now FDA-cleared as a Class II medical device and is the first over-the-counter insulin calculator cleared for individuals aged 2 and older. T1D1 is expected to be live in the AppStore and Google Play Store by October 2025. https://diabetes-connections.com/the-fda-took-down-this-teens-free-bolus-calculator-he-needs-your-help-to-bring-it-back/ XX Metformin has been the standard treatment for type 2 diabetes for more than six decades, yet scientists still do not fully understand how it works. A team from Baylor College of Medicine, working with international collaborators, has now identified an unexpected factor in its effectiveness: the brain. Their findings reveal a brain pathway involved in metformin's glucose-lowering action, pointing to new strategies for treating diabetes with greater precision. The study was published in Science Advances. The researchers concentrated on a small protein called Rap1, located in a region of the brain known as the ventromedial hypothalamus (VMH). They discovered that metformin's ability to lower blood sugar at clinically relevant doses depends on suppressing Rap1 activity in this brain area.   “This discovery changes how we think about metformin,” Fukuda said. “It's not just working in the liver or the gut, it's also acting in the brain. We found that while the liver and intestines need high concentrations of the drug to respond, the brain reacts to much lower levels.”     https://scitechdaily.com/after-60-years-scientists-uncover-hidden-brain-pathway-behind-diabetes-drug-metformin/   XX Looks like GLP-1 pills are moving ahead. Lilly says it's version helped overweight adults with type 2 lose 10% of their body weights and lower A1C. Just two weeks ago, we were talking about how the same drug in people without diabetes had less than the stellar expected results. Orforglipron is a small-molecule pill that is easier to manufacture and package than wildly popular injectable drugs for obesity, such as Lilly's Zepbound and Novo Nordisk's NOVOb.CO rival treatment Wegovy, which are peptide mimics of the appetite-controlling GLP-1 hormone. In the 72-week study of more than 1,600 overweight or obese adults with type 2 diabetes, those who received the 36-milligram highest dose of orforglipron on average shed 10.5% of their weight, or about 23 pounds (10.43 kg), versus 2.2% for those who received a placebo, achieving the main goal of the trial. Patients on the lowest 6 mg dose of the Lilly drug lost 5.5% of their weight. https://www.usatoday.com/story/news/health/2025/08/26/lilly-glp-1-pill-weight-loss/85830686007/ XX     An intervention that combined a low-calorie Mediterranean diet and exercise led to less diabetes incidence in older adults. Men had a greater diabetes risk reduction with the intervention than women. The study was based in Spain, and the diet may not be as easy to adhere to in the U.S. Among nearly 5,000 adults with metabolic syndrome and overweight or obesity in the PREDIMED-Plus trial, those who followed this intervention had a 31% lower risk for type 2 diabetes over 6 years relative to those who received only ad libitum Mediterranean diet advice (aHR 0.69, 95% CI 0.59-0.82). the Mediterranean diet focuses on high intake of plant-based foods, moderate consumption of fish, poultry, and dairy with optional red wine, and low intake of red meats, sweets, and sugar-sweetened beverages. Common foods featured in the diet include extra-virgin olive oil, fruits, vegetables, legumes, nuts, and whole grains. However, Sharon Herring, MD, MPH, and Gina Tripicchio, PhD, MSEd, both of Temple University in Philadelphia, pointed out that this study was conducted solely in Spain, and sticking to this type of diet may be more challenging in countries like the U.S.   "Participants in the study received extra-virgin olive oil to support adherence and retention; in the United States, prices of extra-virgin olive oil have nearly doubled since 2021 due to a combination of factors including climate change, rising production costs, supply chain disruptions, and now tariffs," they noted in an accompanying editorial. "[T]he large number of dietitian contacts during the study may prove difficult to scale broadly in the United States given challenges with health care access and reimbursement for prevention services."         https://www.medpagetoday.com/primarycare/diabetes/117151 XX A group of Canadian researchers has identified an unexpected way to lower blood sugar and protect the liver: by capturing a little-known fuel produced by gut bacteria before it enters the body and causes harm. The findings, published in Cell Metabolism, could open the door to new therapies to treat metabolic diseases like type 2 diabetes and fatty liver disease. Scientists from McMaster University, Université Laval, and the University of Ottawa discovered that a molecule generated by gut microbes can cross into the bloodstream, where it drives the liver to overproduce glucose and fat. By designing a method to trap this molecule in the gut before it reaches circulation, they achieved striking improvements in blood sugar regulation and fatty liver disease in obese mice. https://scitechdaily.com/scientists-discover-a-surprising-new-way-to-fight-diabetes/ XX Dexcom, which specializes in technology for glucose biosensing, will lay off 350 workers, with nearly 200 of them in San Diego, according to the San Diego Union Tribune. The bulk of the local jobs being lost are focused on Dexcom operations and manufacturing. The Dexcom development follows cutbacks to Verily, a life sciences company that is a subsidiary of Alphabet, Google's corporate parent. Verily's work included a project with Dexcom on wearable glucose sensors. CEO Stephen Gillett, in a memo obtained by the publication, said there will be “workforce reductions across Verily.” A representative for Verily confirmed to Business Insider that “we have made the difficult decision to discontinue manufacturing medical devices and will no longer be supporting them going forward.” https://timesofsandiego.com/business/2025/08/27/report-life-sciences-firm-dexcom-lay-off-200-san-diego-workers/ XX Front office changes at Insulet. Eric Benjamin, former chief product and customer experience officer, will take the role of chief operating officer, effective immediately. Manoj Raghunandanan Mu-NOHJ Rug-a-nun-da-nun to the position of chief growth officer, leading Insulet's new growth organization. The appointments are some of CEO Ashley McEvoy's first changes since she was hired in April. The appointments come after McEvoy outlined four priorities for Insulet on an August earnings call:   enhancing the company's commercial capabilities, building Insulet's brand and direct-to-consumer capabilities, driving growth outside of the U.S. and accelerating the pace of innovation. https://www.medtechdive.com/news/insulet-eric-benjamin-manoj-raghunandanan-appointments/758668/ XX   XX Want to highlight The Children's Diabetes Foundation in Colorado – they held a medal ceremony for patients of the Barbara Davis Center who've lived with Type 1 diabetes for 50 years or more. There were 87 medal recipients in the ceremony including Dana Davis, Executive Director of the Children's Diabetes Foundation and the daughter of the founders of the Barbara Davis Center. Davis shared: "When you got Type1 diabetes in the 70s, they thought you shouldn't have children. They thought you weren't going to live past 30 or 40. It was definitely very different," Davis said.   https://www.cbsnews.com/colorado/news/barbara-davis-center-celebrates-colorado-type-1-diabetes-patients-milestone/

In der heutigen Folge sprechen die Finanzjournalisten Anja Ettel und Philipp Vetter über KI-Optimismus bei Dell, eine neue Toniebox-Euphorie in Kinderzimmern und einen Analysten-Push für Siemens. Außerdem geht es um Ulta Beauty, Marvell, Gap, Amazon, Microsoft, Meta, Spotify, IBM, Alphabet, Bristol Myers Squibb, Argenx, Legend Biotech, Summit Therapeutics, Denali Therapeutics, Intellia, Regeneron, Immunocore, Viking Therapeutics, Novo Nordisk und Eli Lilly. Die Tickets zum Finance Summit am 17. September bekommt ihr 40 Euro günstiger – aber nur mit dem exklusiven Code AAA2025, der ihr unter dem folgenden Link eingeben müsst: https://veranstaltung.businessinsider.de/BN5aLV Außerdem könnt ihr unter diesem Link euer Depot hochladen – und mit etwas Glück wird kein Geringerer als Christian W. Röhl euer Depot beim Summit checken und optimieren. https://form.jotform.com/Product_Unit/formular-finance-summit-depot-check Wir freuen uns an Feedback über aaa@welt.de. Noch mehr "Alles auf Aktien" findet Ihr bei WELTplus und Apple Podcasts – inklusive aller Artikel der Hosts und AAA-Newsletter. Hier bei WELT: https://www.welt.de/podcasts/alles-auf-aktien/plus247399208/Boersen-Podcast-AAA-Bonus-Folgen-Jede-Woche-noch-mehr-Antworten-auf-Eure-Boersen-Fragen.html. Der Börsen-Podcast Disclaimer: Die im Podcast besprochenen Aktien und Fonds stellen keine spezifischen Kauf- oder Anlage-Empfehlungen dar. Die Moderatoren und der Verlag haften nicht für etwaige Verluste, die aufgrund der Umsetzung der Gedanken oder Ideen entstehen. Hörtipps: Für alle, die noch mehr wissen wollen: Holger Zschäpitz können Sie jede Woche im Finanz- und Wirtschaftspodcast "Deffner&Zschäpitz" hören. +++ Werbung +++ Du möchtest mehr über unsere Werbepartner erfahren? Hier findest du alle Infos & Rabatte! https://linktr.ee/alles_auf_aktien Impressum: https://www.welt.de/services/article7893735/Impressum.html Datenschutz: https://www.welt.de/services/article157550705/Datenschutzerklaerung-WELT-DIGITAL.html

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma e Biotech world. CDC Director Monarez was fired after less than a month due to internal unrest over new COVID-19 vaccine policies. Novo Nordisk is investing over $500 million in RNA obesity treatments. The FDA has approved updated COVID-19 shots from Pfizer, Moderna, and Novavax with restrictions, causing concern among some groups. Prothena's Alzheimer's drug, PRX012, has shown high rates of brain swelling in Phase I testing. Novo Nordisk is collaborating with other companies on cardiometabolic treatments. The pharma industry is facing challenges and changes, with layoffs and restructurings occurring at various companies. Massachusetts has seen a decline in R&D and biomanufacturing jobs in 2024. Various webinars and events are being held to discuss topics such as pharma manufacturing and data accessibility. Job opportunities in the pharmaceutical industry include positions in business analysis, quality engineering, and project engineering.

Pardon? Microsoft, dat 49 procent van de aandelen van OpenAI in handen heeft, is zelf ineens aan het uitvinden geslagen. Het wil een eigen variant van ChatGPT hebben, om zo minder afhankelijk te zijn. Op zijn zachts gezegd een opvallend besluit, aangezien ze al 13 miljard dollar hebben uitgegeven aan de ontwikkeling van ChatGPT. Deze aflevering hebben we het over deze apart stap. Of is het juist een slimme tactiek van Microsoft om zelf te investeren in kunstmatige intelligentie?Bitcoin-bedrijf AMBTS komt ook voorbij. Het wil dolgraag naar de Amsterdamse beurs en lijkt een belangrijke horde daarvoor genomen te hebben. Vraag is alleen of beleggers er op zitten te wachten. NovoNordisk én Nike komen voorbij. Beide hebben het lastig, maar het Deense bedrijf maakt het wel heel bont. De groei van NovoNordisk holt zo terug dat het de hele groeiverwachting van de Deense economie naar beneden trekt. Verder hebben we het over de Fed. Minister Eelco Heinen maakt zich inmiddels zorgen over het 'inbeuken' van Trump op de centrale bank. En we gaan je voorbereiden op een periode zonder kwartaalcijfers. Nu het cijferseizoen zo goed als voorbij is, waar moet je nu op letten?See omnystudio.com/listener for privacy information.

Join panelists Robert Kushner, MD, Jamy Ard, MD, and Jaime Almandoz, MD, to learn about BMI as a measure of excess adiposity, exploring both its strengths and limitations. Speakers:  -          Bob Kushner, MD  -          Jamy Ard, MD, FTOS -          Jaime Almandoz, MD, MBA, MRCPI, FTOS   This podcast is sponsored by Novo Nordisk and is intended for clinicians. Novo Nordisk is a registered trademark of Novo Nordisk A/S. All other trademarks, registered or unregistered, are the property of their respective owners. © 2025 Novo Nordisk All rights reserved. US24OB00077 June 2025

In this episode of The Daily Mastermind, host George Wright III welcomes an inspiring guest, the founder and CEO of Florida's Cotton Clouds, Onahira Rivas. She talks about her entrepreneurial journey from starting a business as a child to scaling multiple multimillion-dollar ventures. They share insightful lessons on leveraging corporate experience, implementing systems and SOPs, and the importance of sales and marketing as a foundation. The episode introduces the Bold Business Framework designed to help six and seven-figure business owners transform their businesses into legacy enterprises through sales and marketing, operational systems, investor readiness, and growth strategies. Real-world examples, including a car dealership's success story, illustrate the practical application of the framework. 02:05 Corporate Experience and Transition to Entrepreneurship04:07 Building and Scaling a Business06:22 Creating a Legacy and Manufacturing in America10:55 The Bold Business Framework17:57 Case Study: Transforming a Car Dealership23:27 Mindset Shifts for EntrepreneursYou have GREATNESS inside you. I BELIEVE in You. Let's Make Today the Day You Unleash Your Potential!George Wright IIICEO, The Daily Mastermind | Evolution X_________________________________________________________P.S. Whenever you're ready, here are ways I can help you…Get to know me:1. Subscribe to The Daily Mastermind Podcast- daily inspiration, motivation, education2. Follow me on social media Facebook | Instagram | Linkedin | TikTok | Youtube3. Get the Prosperity Pillars Poster I Developed over 20 years from my Mentors.Work with me:My mission is to help you Master Your Mind, Money, & Business, and I firmly believe:It's Never Too Late to Create the Life You Were Meant to Live…a LIFESTYLE of Health, Wealth, and Happiness. Here are ways I've been able to help thousands of people over the past 20 years…About the Guest: Onahira RivasOnahira Rivas is the founder and CEO of Florida's Cotton Clouds, the first woman-led cotton manufacturing facility in the U.S. With over two decades of global leadership experience at companies like Novo Nordisk and Bristol Myers Squibb, she has launched and scaled multimillion dollar brands across pharma, retail, and consumer goods. Onahira has introduced hundreds of products to major retailers and now focuses on purpose-driven business. Her work is rooted in values like resilience, transparency, and faith. She's a member of the Forbes Business Council, a winner of The Blox TV competition, and a passionate advocate for U.S.-based manufacturing and female leadership in business.Guest ResourcesValiant CEO Article: https://valiantceo.com/onahira-rivas-of-floridas-cotton-clouds-resilient-leadership-amidst-business-challenges/Website: https://onahirarivas.com/Florida Cotton Clouds Website: https://floridascottonclouds.com/ Meet with Onahira: https://intro.co/ONAHIRARIVAS?source=introFacebook & Instagram: @onahirarivasTikTok: Tiktok@onahirarivasLinkedIn: https://www.linkedin.com/in/onahirarivas